Sequoia Capital Invests In Saint Lucia Consulting For U.S.-Linked Cancer Treatment Program
This article was originally published in PharmAsia News
As an exclusive partner of U.S. Partners HealthCare International (PHI), Saint Lucia Consulting has received investment funds from Sequoia Capital and will provide cancer evaluation services (CES) for Chinese patients who are seeking medical treatment in U.S.
You may also be interested in...
The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.